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In 50 consecutive children admitted to the intensive care unit
with the clinical diagnosis of dengue hemorrhagic fever
(DHF)/dengue shock syndrome (grade III or IV), 20 patients
with mild DHF (grade I or II), and 20 healthy control pa-
tients, the plasma lipid profile was measured. Levels of total
plasma cholesterol, high-density lipoprotein, and low-density
lipoprotein were significantly decreased in patients with the
severest cases, compared with patients with mild DHF and
healthy controls. Changes in the plasma lipid profile differ-
entiate between patients with different stages of DHF disease
severity and could be used as a potential predictor for clinical
outcome.
Lipoproteins are thought to play a pathophysiological role in
the host’s immune response during severe infection [1].
Changes in the lipoprotein profile during infection probably
are primarily cytokine induced [2]. In patients with bacterial
infection, lipoproteins, including very low–density lipoprotein
VLDL, bind endotoxin and thereby neutralize the toxic effects
of endotoxin [3, 4]. Interactions between microorganisms and
lipoproteins also occur in viral infections. Certain viruses use
low-density lipoprotein (LDL) receptors to enter the cell, which
implies that LDL may compete with viruses for these cellular
receptors [5]. Therefore, high LDL levels may be beneficial
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because they decrease virus uptake by cells. Lipoproteins also
bind viruses and neutralize their toxic effects [6, 7].
In the present prospective study, we investigated whether
changes in the serum lipid levels are found in patients with
dengue hemorrhagic fever (DHF) and whether such changes
may be relevant to clinical outcome. The study was performed
in Semarang, Central Java, Indonesia, at the Dr. Kariadi Uni-
versity Hospital of the University of Diponegoro. Dengue is
endemic in Java and there are yearly outbreaks of infection.
Consecutive patients (children) with a clinical diagnosis of se-
vere DHF (i.e., grade III or IV), as determined by the criteria
of the World Health Organization (WHO), who were admitted
to the pediatric intensive care unit during July–October 1996
were included [8]. In addition, 20 age-related patients with mild
DHF (i.e., grade I and II) admitted to the pediatric ward and
20 age-related, nonfebrile, healthy children were included. The
study protocol received approval from the Institutional Review
Board of the University Hospital of Diponegoro University in
Semarang, and informed consent was obtained from children’s
parents or guardians prior to study inclusion.
The clinical diagnosis of grade I and II DHF was made on the
basis of abrupt onset of fever, thrombocytopenia (! 9100  10
platelets/L), evidence of plasma leakage (manifested by hemo-
concentration or signs of serous effusion), and a hemorrhagic
tendency. A positive tourniquet test result and/or easy bruising
in the absence of spontaneous bleeding differentiates DHF I from
DHF II. A diagnosis of DHF III was made if there was additional
circulatory failure manifested by a rapid and weak pulse and
narrowing pulse pressure (!20 mm Hg) or hypotension in the
presence of a cold clammy skin and restlessness. Patients with
undetectable blood pressure or pulse were given a diagnosis of
DHF IV [8].
In all subjects, the plasma lipid profile (i.e., cholesterol, high-
density lipoprotein [HDL], LDL, and triglyceride levels) was
determined. The presence of dengue virus was objectively con-
firmed by serologic assays. A capture and indirect ELISA de-
tected dengue-specific IgM and IgG antibodies in serum sam-
ples, in accordance with a procedure described elsewhere [9].
Blood samples were obtained from all patients for culture to
exclude bacterial infections. Blood samples for analysis of the
serum lipid profile and cytokines were obtained on the day of
admission. Venous blood samples were drawn into vacutainer
tubes that contained 0.105 mL of sodium citrate (1 v; Becton
Dickinson). All blood samples were immediately immersed in
melting ice and subsequently centrifuged at 4C for 20 min at
1600g. Plasma samples were stored at 70C until assayed.
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Figure 1. Box plots of serum cholesterol levels in control subjects
and patients with dengue hemorrhagic fever (DHF) on day of admission
to the hospital. Box plots show the median (center horizontal line), in-
terquartile range (the 25th to the 75th percentile [box]), and the 5th and
95th percentiles (whiskers). P values were determined by the Kruskal-
Wallis test for comparison of 3 groups. The median cholesterol level in
the control group was 3.45 mmol/L (interquartile range, 3.08–3.70 mmol/
L); in the mild DHF group, it was 3.10 mmol/L (interquartile range,
2.80–3.73 mmol/L); and in the dengue shock syndrome (DSS) group, it
was 2.35 mmol/L (interquartile range, 1.85–2.90 mmol/L).
Figure 2. Box plots of serum high-density lipoprotein (HDL) levels in
control subjects and patients with dengue hemorrhagic fever (DHF) on
day of admission to the hospital. Box plots show the median (center
horizontal line), interquartile range (the 25th to the 75th percentile [box]),
and the 5th and 95th percentiles (whiskers). P values were determined
by the Kruskal-Wallis test for comparison of 3 groups. The median HDL
level in the control group was 1.25 mmol/L (interquartile range, 1.13–1.39
mmol/L); in the mild DHF group, it was 0.72 mmol/L (interquartile range,
0.5–0.87 mmol/L); and in the dengue shock syndrome (DSS) group, it
was 0.21 mmol/L (interquartile range, 0.14–0.37 mmol/L). Outliers are
presented as asterisks.
Plasma levels of cholesterol and triglycerides were determined
by enzymatic methods that used commercially available re-
agents (CHOD-PAP reagent; Roche) by means of a Hitachi 747
automatic analyzer. Plasma HDL-cholesterol concentrations
were determined after precipitation of LDL, VLDL, and chy-
lomicrons by use of phosphotingsta-Mg2 [10]. LDL-choles-
terol concentrations were calculated according to the Friede-
wald formula [11].
The plasma levels of the analytes measured are presented as
median values with their corresponding interquartile ranges
(IQRs) and 95% CIs. The Mann-Whitney U test was used to
compare the respective plasma levels among the different
groups: healthy control subjects, patients with mild DHF, and
patients with severe DHF. The Kruskal-Wallis test was used for
comparison of the 3 groups. Two-tailed P values of !.05 were
considered to indicate statistical significance. Analyses were per-
formed by use of the statistical software SPSS, version 9.0
(SPSS).
From July 1996 through October 1996, a total of 50 con-
secutive children (mean , years) with a clin-age  SD 6.5  2.8
ical diagnosis of DHF III and IV were enrolled in the study.
During follow-up, 13 patients (26%) in the dengue shock syn-
drome group (i.e., those with DHF grade III or IV) died of
shock or bleeding complications in the intensive care unit. The
baseline characteristics of patients in the severe DHF group
who survived were comparable to those of patients who did
not survive with regard to age, sex, disease severity at admission,
and day of admission to the hospital (mean  SD, 4.3  0.9
vs. ) [12]. The mild DHF group also did not differ4.1  1.4
from the severe DHF group with regard to age, sex, and ad-
mission day, although the patients in the latter group already
had evidence of severe infection at admission. The 20 children
in the healthy control group were similar to the other groups
in age and sex.
The clinical diagnosis of DHF was confirmed by serologic
assay in all patients, either by an IgM response or a 4-fold
increase in IgG titers. Antibody profiles were typical for sec-
ondary dengue infection. All patients were of Javanese origin,
excluding racial differences. In all patients, blood cultures re-
vealed no bacterial growth. Patients who had severe DHF were
compared with patients who had mild DHF and with healthy
control subjects, which revealed that groups differed signifi-
cantly with regard to serum cholesterol, HDL, and LDL levels;
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Figure 3. Box plots of low-density lipoprotein (LDL) levels in control
subjects and patients with dengue hemorrhagic fever (DHF) on day of
admission to the hospital. Box plots show the median (center horizontal
line), interquartile range (the 25th to the 75th percentile [box]), and the
5th and 95th percentiles (whiskers). P values were determined by the
Kruskal-Wallis test for comparison of 3 groups. The median LDL level in
the control group was 1.79 mmol/L (interquartile range, 1.30–2.26 mmol/
L); in the mild DHF group, it was 1.77 mmol/L (interquartile range,
1.42–2.18 mmol/L); and in the dengue shock syndrome (DSS) group, it
was 1.04 mmol/L (interquartile range, 0.78–1.67 mmol/L).
Figure 4. Box plots of triglyceride levels in control subjects and pa-
tients with dengue hemorrhagic fever (DHF) on day of admission to the
hospital. Box plots show the median (center horizontal line), interquartile
range (the 25th to the 75th percentile [box]), and the 5th and 95th
percentiles (whiskers). P values were determined by the Kruskal-Wallis
test for comparison of 3 groups. The median triglyceride level in the
control group was 0.83 mmol/L (interquartile range, 0.74–1.44 mmol/L);
in the mild DHF group, it was 1.69 mmol/L (interquartile range, 1.05–2.48
mmol/L); and in the dengue shock syndrome (DSS) group, it was 2.17
mmol/L (interquartile range, 1.54–2.67 mmol/L). Outliers are presented
as asterisks.
the lowest levels occurred in patients with severest disease, ac-
cording to the Kruskal-Wallis test for comparison of total cho-
lesterol, HDL, and LDL levels ( ; figures 1–3). In a su-P ! .001
banalysis of the patients with severe DHF (i.e., grade III and
IV) who survived ( ) and who did not survive (n p 37 n p
), the lowest serum cholesterol, HDL, and LDL levels were13
noted in the nonsurvivor group. Patients who survived were
compared with those who did not survive with regard to me-
dian values of plasma lipid profile with 25th and 75th IQRs;
the Mann-Whitney U test was used for comparison. The plasma
cholesterol levels were 2.70 versus 2.05 mmol/L (IQR, 2.15–3.10
vs. 1.28–2.28 mmol/L; ), the plasma HDL levels wereP ! .03
0.25 versus 0.14 mmol/L (IQR, 0.17–0.42 vs. 0.13–0.24 mmol/
L; ), and the plasma LDL levels were 1.32 versus 0.83P ! .03
mmol/L (IQR, 0.83–1.76 vs. 0.61–1.11 mmol/L; ), re-P ! .04
spectively. The contrary was demonstrated for the triglyceride
levels, for which the highest levels measured were noted in
patients with the most severe cases, although values were not
significantly different among the 3 groups (figure 4). In the
subanalyses of patients who survived versus those who did not
survive, the highest triglyceride levels were also noted in the
patients who did not survive (2.26 mmol/L [IQR, 1.50–3.29
mmol/L] vs. 2.34 mmol/L [IQR, 1.76–3.10 mmol/L]; ).P p NS
In the present study, we found a significant difference in the
plasma cholesterol, HDL, and LDL levels among patients with
mild DHF (i.e., grade I or II), severe DHF (i.e., grade III or
IV), and a control group of healthy subjects, as well as between
patients who did and patients who did not survive in the severe
DHF group. The observed differences could be considered to
represent surrogate markers for severe infection, because they
could represent actual markers of risk for severe infection and
poor clinical outcome. In particular, the findings in the severe
DHF group suggested that cholesterol, HDL, and LDL levels
can be used as prognostic markers to predict clinical outcome.
A major question is, what mechanism is behind these lipopro-
tein changes? From data largely derived from experimental
studies involving humans and animals, we know that lipid me-
tabolism and cytokine production are linked. The interaction
between cytokines and lipoproteins is bidirectional. Lipids are
involved in the regulation of cytokine levels and thereby modify
the host immune response [2]. On the other hand, cytokines
are known to have the ability to modify lipid metabolism. TNF-
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a and IL-1 decrease serum cholesterol levels, probably by in-
fluencing the enzyme hydroxymethylglutaryl (HMG) coenzyme
A (CoA) reductase. Also, the decrease in HDL levels observed
during infection is probably enzyme mediated. TNF-a may
decrease the plasma activity of lecithin cholesterol acyl trans-
ferase (LCAT), the enzyme responsible for esterifying free cho-
lesterol in HDL [13]. The increase in triglyceride levels observed
during infection may be the result of an increase in lipolysis
[14] and de novo fatty acid synthesis in the liver [14, 15]. This
process is also enzyme mediated by increasing the activity of
the CoA carboxylase enzyme. In accordance with these findings,
we and others [16] have found elevated levels of TNF-a and
IL-1 in patients with DHF.
Our findings are in line with the results of studies of patients
with illnesses comparable to severe DHF [17, 18] and of a study
of dengue virus–infected patients [19] published elsewhere. Ray
et al. [19] reported differences in cholesterol and triglyceride
levels in dengue virus–infected patients with different degrees
of severity. However, no HDL or LDL concentrations were
measured, and details on cholesterol and triglyceride levels in
association with clinical outcome were missing. We demon-
strated that the plasma lipid profile differs according to the
stage of DHF disease severity and that cholesterol, HDL, and
LDL levels could be used as potential predictors of clinical
outcome. The question of whether we can use this in clinical
practice has to be answered in a future, prospective, follow-up
study.
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